Jonathan Aliota, MD
Interventional Cardiology · Houston, TXNPI 1598712812
Payments from drug & device makers
Across 291 payments — averaging $365.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$86K
- Shockwave Medical, Inc$8K
- Medtronic$3K
- Abbott$3K
- Abiomed$2K
- Edwards Lifesciences$1K
- plus $4K from 20 others
What the payments were for
- Consulting fees$8,8508%
- Speaking & faculty fees$69,93866%
- Travel & lodging$10,91010%
- Food & beverage$16,53216%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 108 | $85,522 |
| Shockwave Medical, Inc | 12 | $7,992 |
| Medtronic(2 entities) | 43 | $3,227 |
| Abbott | 39 | $2,941 |
| Abiomed | 18 | $1,769 |
| Edwards Lifesciences | 14 | $1,110 |
| Angiodynamics, Inc. | 21 | $962 |
| Cordis US CORP. | 2 | $511 |
| Digirad Health, Inc | 1 | $264 |
| Johnson & Johnson | 2 | $250 |
| Saranas, Inc. | 2 | $233 |
| Cardiovascular Systems Inc. | 2 | $185 |
| GE HealthCare | 2 | $171 |
| Teleflex LLC | 1 | $170 |
| Cagent Vascular Inc | 3 | $152 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $148 |
| Philips North America LLC | 5 | $128 |
| Bard Peripheral Vascular, Inc. | 2 | $112 |
| Avinger Inc. | 1 | $110 |
| Cvrx, Inc. | 1 | $75 |
| Artivion, Inc. | 1 | $64 |
| Biotronik Inc. | 1 | $42 |
| Amgen | 2 | $40 |
| Pfizer | 1 | $23 |
| Veryan Medical Incorporated | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL VASCULAR ACCESS$42,398
- CROSSBOSS$13,000
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$7,531
- GENERAL - THERAPIES$2,950
- Impella$1,505
- ClosureFast$1,309
- CARDIOMEMS$1,028
- VenaSeal$551
- OPTIS$424
- MYNX CONTROL$416
- CARDIUS$264
- XARELTO$250
- GENERAL - STENTS$243
- SYNERGY$220
- Prostar XL surgical system$186
- GUIDELINER$170
- RESOLUTE ONYX$153
- AVVIGO Guidance System$142
- OPTICROSS$134
- ONYX FRONTIER$131
How this compares
$106,229 in reported general payments places this provider in the 85th percentile of 686 interventional cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 474 | $501,622 |
| XareltoRivaroxaban | 283 | $267,112 |
| EntrestoSacubitril/Valsartan | 49 | $68,343 |
| Repatha SureclickEvolocumab | 66 | $47,935 |
| Rosuvastatin Calcium | 513 | $24,361 |
| BrilintaTicagrelor | 22 | $16,328 |
| Pravastatin Sodium | 302 | $12,988 |
| Praluent PenAlirocumab | 12 | $12,696 |
| ClopidogrelClopidogrel Bisulfate | 448 | $12,266 |
| Valsartan | 147 | $12,063 |
| Atorvastatin Calcium | 271 | $8,510 |
| Flecainide Acetate | 139 | $8,033 |
| Losartan Potassium | 268 | $6,710 |
| Metoprolol Succinate | 231 | $6,025 |
| Amiodarone Hcl | 57 | $4,499 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $23 | $501,622474 claims |
| Johnson & JohnsonXarelto | $250 | $267,112283 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 686 interventional cardiology providers in Texas.
Other interventional cardiology in Houston
- Neal KleimanHouston$4.8M
- Juan GranadaHouston$4.3M
- Abhijeet DhobleHouston$2.7M
- John IsaacHouston$1.8M
- Amir KashaniHouston$1.3M
- Biswajit KarHouston$785K
- Michele SartoriHouston$603K
- Guilherme SilvaHouston$516K
- Sachin KumarHouston$446K
- Marwan JumeanHouston$427K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.